The answer — based on this prospective study of darunavir, etravirine, and raltegravir combined — is an emphatic yes. Multiclass treatment–experienced patients from 49 HIV clinics in France ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback